全身免疫炎症指数在乳腺癌患者预后中预测价值的meta分析

摘要
图/表
参考文献(43)
相关文章 (15)

全文: PDF (1263 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的研究全身免疫炎症指数（SII）在乳腺癌患者预后中的预测价值。方法计算机检索PubMed、Cochrane Library、Embase、Web of Science数据库，收集2015年1月—2020年7月所有关于SII与乳腺癌患者预后的研究，采用Stata 12.0及Review Manager 5.3软件进行数据分析。结果本研究最终纳入8项研究，包括2642例乳腺癌患者。meta分析结果显示高SII乳腺癌患者肿瘤直径＞2.0 cm占比高于低SII乳腺癌患者（OR = 1.49，95%CI：1.19~1.85，P = 0.0004）。高SII乳腺癌患者淋巴结转移占比高于低SII乳腺癌患者（OR = 1.38，95%CI：1.12~1.69，P = 0.002）。高SII乳腺癌患者总生存期短于低SII乳腺癌患者（HR = 2.06，95%CI：1.55~2.74，P ＜ 0.000 01）。高SII对乳腺癌术后患者无病生存期短于低SII乳腺癌患者（HR = 1.93，95%CI：1.63~2.30，P ＜ 0.000 01）。结论 SII可作为临床预测乳腺癌患者预后的可靠指标。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	谷静静1 张维东2 陈丹丹1 张建国1 黄关宏3

关键词 ：全身免疫炎症指数, 乳腺癌, meta分析, 预后

Abstract：Objective To investigated the predictive value of systemic immune inflammatory index (SII) in the prognosis of patients with breast cancer. Methods PubMed, Cochrane Library, Embase, and Web of Science databases were searched by computer, all the studies on SII and prognosis of patients with breast cancer were collected from January 2015 to July 2020. Stata 12.0 and Review Manager 5.3 software were used for data analysis. Results A total of eight studies were included in this study, including 2642 cases patients with breast cancer. Meta-analysis results showed that the proportion of tumor diameter > 2.0 cm in high SII patients with breast cancer was higher than that in low SII patients with breast cancer (OR = 1.49, 95%CI: 1.19-1.85, P = 0.0004). The proportion of lymph node metastases in high SII patients with breast cancer was higher than that in low SII patients with breast cancer (OR = 1.38, 95%CI: 1.12-1.69, P = 0.002). Overal survival in high SII patients with breast cancer was shorter than those with low SII breast cancer (HR = 2.06, 95%CI: 1.55-2.74, P < 0.000 01). Distase free survival in high SII patients with breast cancer was shorter than that in low SII patients with breast cancer (HR = 1.93, 95%CI: 1.63-2.30, P < 0.000 01). Conclusion SII can be used as a reliable indicator to predict the prognosis of patients of breast cancer.

Key words： Systemic immune inflammation index Breast cancer Meta-analysis Prognosis

基金资助: 江苏省卫生计生委科研课题（H2017040）。

通讯作者: 黄关宏（1968.4-），男，博士，主任医师，蚌埠医学院附属连云港市第二人民医院副院长；研究方向：肿瘤放射治疗学。

作者简介: 谷静静（1993.4-），女，蚌埠医学院2018级肿瘤放射治疗学专业在读硕士研究生；研究方向：肿瘤放射治疗学。

引用本文:

谷静静1 张维东2 陈丹丹1 张建国1 黄关宏3. 全身免疫炎症指数在乳腺癌患者预后中预测价值的meta分析[J]. 中国医药导报, 2021, 18(14): 93-97.
GU Jingjing1 ZHANG Weidong2 CHEN Dandan1 ZHANG Jianguo1 HUANG Guanhong3. Meta-analysis of the predictive value of systemic immune inflammatory index in the prognosis of patients with breast cancer. 中国医药导报, 2021, 18(14): 93-97.

链接本文:

https://www.yiyaodaobao.com.cn/CN/ 或 https://www.yiyaodaobao.com.cn/CN/Y2021/V18/I14/93

1] Wu ZY，Kim HJ，Lee JW，et al. Long-term Oncologic Outcomes of Immediate Breast Reconstruction vs Conventional Mastectomy Alone for Breast Cancer in the Setting of Neoadjuvant Chemotherapy [J]. JAMA Surg，2020，155（12）：1142-1150.
[2] Wang K，Shen T，Siegal GP，et al. The CD4/CD8 ratio of tumor infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer [J]. Hum Pathol，2017，69：110-117.
[3] Liu C，Sun B，Xu B，et al. A panel containing PD-1，IL-2Rα，IL-10，and CA15-3 as a biomarker to discriminate breast cancer from benign breast disease [J]. Cancer Manag Res，2018，10：1749-1761.
[4] Zhong JH，Huang DH，Chen ZY. Prognostic role of systemic immune-inflammation index in solid tumors：a systematic review and meta-analysis [J]. Oncotarget，2017，8（43）：75381-75388.
[5] Hu Q，Hisamatsu T，Haemmerle M，et al. Role of platelet-derived Tgfβ1 in the progression of ovarian cancer [J]. Clin Cancer Res，2017，23（18）：5611-5621.
[6] Stang A. Critical evalution of the Newcastle-Ottawa Scale for the assessment of the quality of nonrandomized syudies in meta-ananlyses [J]. Eur J Idemiol，2010，9（25）：603-605.
[7] Mantel N，Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease [J]. J Natl Cancer Inst，1959，4（22）：719-748.
[8] Begg CB，Mazumdar M. Operating characteristics of a rank correlation test for publication bias [J]. Biometrics，1994， 50（4）：1088-1101.
[9] Egger M，Davey Smith G，Schneider M，et al. Bias in meta-analysis detected by a simple，graphical test [J]. BMJ，1997，315（7109）：629-634.
[10] Chen L，Kong X，Wang Z，et al. Pre-treatment systemic immune-inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy [J]. J Cell Mol Med，2020，24（5）：2993-3021.
[11] Wang P，Yue W，Li W，et al. Systemic immune-inflammation index and ultrasonographic classification of breast imaging reporting and data system predict outcomes of triple-negative breast cancer [J]. Cancer Manag Res，2019， 11：813-819.
[12] Sun Y，Li W，Li AJ，et al. Increased systemic immune-inflammation index independently predicts poor survival for hormone receptor-negative，HER2-positive breast cancer patients [J]. Cancer Manag Res，2019，11：3153-3162.
[13] Li QX，Shi DJ，Zhang LX，et al. Association of body mass and systemic immune-inflammation indices with endocrine therapy resistance in luminal breast cancers [J]. J Int Med Res，2019，47（5）：1936-1947.
[14] Jiang L，Fang J，Ding J. High Systemic Immune-Inflammation Index Predicts Poor Survival in Patients with Human Epidermal Growth Factor Receptor-2 Positive Breast Cancer Receiving Adjuvant Trastuzumab [J]. Cancer Manag Res，2020，12：475-484.
[15] Hua X，Long ZQ，Zhang YL，et al. Prognostic Value of preoperative Systemic Immune-Inflammation Index in Breast Cancer：A Propensity Score-Matching Study [J]. Front Oncol，2020，10：580.
[16] De Giorgi U，Mego M，Scarpi E，et al. Association between circulating tumor cells and peripheral blood monocytes in metastatic breast cancer [J]. Ther Adv Med Oncol，2019，11：1758835919866065.
[17] Liu J，Shi Z，Bai Y，et al. Prognostic significance of systemic immune-inflammation index in triple-negative breast cancer [J]. Cancer Manag Res，2019，11：4471-4480.
[18] An G，Wu F，Huang S，et al. Effects of CCL5 on the biological behavior of breast cancer and the mechanisms of its interaction with tumor-associated macrophages [J]. Oncol Rep，2019，42（6）：2499-2511.
[19] Wellenstein MD，Coffelt SB，Duits DEM，et al. Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis [J]. Nature，2019，572（7770）；538-542.
[20] Schroth W，Büttner FA，Kandabarau S，et al. Gene Expression Signatures of BRCAness and Tumor Inflammation Define Subgroups of Early-Stage Hormone Receptor-Positive Breast Cancer Patients [J]. Clin Cancer Res，2020，26（24）：6523-6534.
[21] Zhang Y，Chandra V，Riquelme Sanchez E，et al. Interleukin-17-induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer [J]. J Exp Med，2020，217（12）：e20190354.
[22] Floris G，Richard F，Hamy AS，et al. Body Mass Index and Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer [J]. J Natl Cancer Inst，2021，113（2）：146-153.
[23] Mijic S，Dabrosin C. Platelet activation in situ in breasts at high risk of cancer：relationship with mammographic density and estradiol [J]. J Clin Endocrinol Metab，2021， 106（2）：485-500.
[24] Mammadova-Bach E，Gil-Pulido J，Sarukhanyan E，et al. Platelet glycoprotein VI promotes metastasis through interaction with cancer cell-derived galectin-3 [J]. Blood，2020，135（14）：1146-1160.
[25] Zhong JH，Huang DH，Chen ZY. Prognostic role of systemic immune-inflammation index in solid tumors：A systematic review and meta-analysis [J]. Oncotarget，2017，8（43）：75381-75388.